Research programme: targeted cancer therapeutics - NantBioScience
Latest Information Update: 23 Jan 2014
At a glance
- Originator NantBioScience
- Class Albumins
- Mechanism of Action KRAS protein inhibitors; P53 gene modulators; Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Jan 2014 Preclinical trials in Cancer in USA (unspecified route)